Dyne Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 29 →Insiders1 insider bought $274,840 in 7 open-market buys. 6 insiders sold $65.1M, all 82 sales on a 10b5-1 plan.→HoldersBlackRock 7.5%Jupiter Topco 7.2%FMR 6.8%→PeersClosest companies: DSGN, IDYA, PEPG→
From the filings
Figures
- Net income
- −$73.2Mlast 12 months
- Operating cash flow
- −$442.2Mlast 12 months
- Cash and equivalents
- $676.1Mat the last balance sheet
- Total debt
- $199.3Mat the last balance sheet
- Shares outstanding
- 165.7M shareson issue